Table 1.
Main clinic-pathologic characteristics.
| Characteristics | Overall N = 2489 (%) | HER2-0a N = 450 (%) | HER2-lowa N = 1023(%) | HER2-positivea N = 1016 (%) | P value |
|---|---|---|---|---|---|
| Age, years (median, range) | 50 (21–86) | 49 (26–77) | 50 (22–86) | 51 (21–77) | 0.014 |
| <50 | 1183 (47.5) | 226 (50.2) | 510 (49.9) | 457 (44.0) | |
| ≥50 | 1306 (52.5) | 224 (49.8) | 513 (50.1) | 569 (56.0) | |
| Menstruation | 0.015 | ||||
| Pre/peri-menopausal | 1327 (53.3) | 245 (54.4) | 575 (56.2) | 507 (49.9) | |
| Post-menopausal | 1162 (46.7) | 205 (45.6) | 448 (43.8) | 509 (50.1) | |
| Histology | 0.181 | ||||
| IDC | 2353 (94.5) | 427 (94.9) | 957 (93.5) | 909 (95.4) | |
| non-IDC | 136 (5.5) | 23 (5.1) | 66 (6.5) | 47 (4.6) | |
| Grade | 0.005 | ||||
| I | 39 (1.6) | 15 (3.3) | 13 (1.3) | 11 (1.1) | |
| II | 1064 (42.8) | 181 (40.2) | 472 (46.1) | 411 (40.5) | |
| III | 605 (24.3) | 128 (28.4) | 239 (23.4) | 238 (23.4) | |
| NA | 781 (31.4) | 126 (28.0) | 299 (29.2) | 356 (35.0) | |
| Clinical TNM | <0.001 | ||||
| I | 155 (6.2) | 26 (5.8) | 54 (5.3) | 75 (7.4) | |
| II | 1591 (63.9) | 308 (68.4) | 641 (62.7) | 642 (63.2) | |
| III | 737 (29.6) | 114 (25.3) | 325 (31.8) | 298 (29.3) | |
| NA | 6 (0.2) | 2 (0.4) | 3 (0.3) | 1 (0.1) | |
| Primary ER | <0.001 | ||||
| Positive | 1672 (67.2) | 286 (63.6) | 803 (78.5) | 583 (57.4) | |
| Negative | 817 (32.8) | 164 (36.4) | 220 (21.5) | 433 (42.6) | |
| Primary PR | <0.001 | ||||
| Positive | 1479 (59.4) | 268 (59.6) | 717 (70.1) | 493 (48.6) | |
| Negative | 1010 (40.6) | 182 (40.4) | 306 (29.9) | 522 (51.4) | |
| Primary Ki67 | <0.001 | ||||
| <14% | 314 (12.6) | 73 (16.2) | 155 (15.2) | 86 (8.5) | |
| ≥14% | 2145 (86.2) | 370 (82.2) | 860 (84.1) | 915 (90.1) | |
| NA | 30 (1.2) | 7 (1.6) | 8 (0.8) | 15 (1.4) | |
| Breast Surgery | <0.001 | ||||
| Mastectomy | 2191 (88.0) | 376 (83.6) | 891 (87.1) | 924 (90.9) | |
| BCS | 298 (12.0) | 74 (16.4) | 132 (12.9) | 92 (9.1) | |
| Axillary Surgery | 0.086 | ||||
| SLNB | 220 (8.8) | 30 (6.7) | 87 (8.5) | 103 (10.1) | |
| ALND ± SLNB | 2269 (91.2) | 420 (93.3) | 936 (91.5) | 913 (89.9) | |
| NAC strategy | <0.001 | ||||
| Anthracycline + Taxane | 1670 (67.1) | 342 (76.0) | 822 (80.4) | 506 (49.8) | |
| Anthracycline | 161 (6.5) | 41 (9.1) | 77 (7.5) | 43 (4.2) | |
| Taxane | 646 (26.0) | 64 (14.2) | 118 (11.5) | 464 (45.7) | |
| Others/NA | 12 (0.5) | 3 (0.7) | 6 (0.6) | 3 (0.3) | |
| NAC Cycle | 0.450 | ||||
| 4–6 | 1562 (62.8) | 281 (62.4) | 629 (61.5) | 652 (64.2) | |
| >6 | 927 (37.2) | 169 (37.6) | 394 (38.5) | 364 (35.8) | |
| Breast pCR | <0.001 | ||||
| No | 1797 (72.2) | 352 (78.2) | 812 (79.4) | 633 (62.3) | |
| Yes | 692 (27.8) | 98 (21.8) | 211 (20.6) | 383 (37.7) |
HER2 human epidermal growth factor receptor-2, IDC invasive ductal carcinoma, NA not available, ER estrogen receptor, PR progesterone receptor, TBCS breast-conserving surgery, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, NAC neoadjuvant chemotherapy, pCR pathological complete response.
aHER2 status is according to core needle biopsy specimen before NAC.